DaVita (BSP:DVAI34) Tax Provision : R$-1,191 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is DaVita Tax Provision?

DaVita's tax provision for the three months ended in Mar. 2024 was R$-328 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was R$-1,191 Mil.

DaVita Tax Provision Historical Data

The historical data trend for DaVita's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Tax Provision Chart

DaVita Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-1,147.73

-1,615.09

-1,734.54

-1,039.05

-1,078.52

DaVita Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															-228.94	-236.95	-340.02	-286.61	-327.70

DaVita Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1,191 Mil.

DaVita (BSP:DVAI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

DVA:USA TRL:Germany

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (BSP:DVAI34) Headlines

No Headlines